Jason H Karnes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/629/publications.pdf

Version: 2024-02-01

59 papers	1,673 citations	361413 20 h-index	315739 38 g-index
60 all docs	60 docs citations	60 times ranked	3801 citing authors

#	Article	IF	Citations
1	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	6.7	31
2	Role of the gut microbiome in cardiovascular drug response: The potential for clinical application. Pharmacotherapy, 2022, 42, 165-176.	2.6	5
3	PharmGKB summary. Pharmacogenetics and Genomics, 2022, Publish Ahead of Print, .	1.5	1
4	ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. Blood, 2022, 140, 274-284.	1.4	9
5	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	5.6	19
6	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. Blood Advances, 2022, 6, 4137-4146.	5.2	7
7	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLAâ€B Genotypes and Phenytoin Dosing: 2020 Update. Clinical Pharmacology and Therapeutics, 2021, 109, 302-309.	4.7	102
8	Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American Journal of Cardiovascular Drugs, 2021, 21, 205-217.	2.2	3
9	Reply to Non and Chang: Challenging the Role of Genetic Ancestry in Explaining Racial/Ethnic Health Disparities. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 398-399.	5.6	0
10	Multiâ€site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clinical and Translational Science, 2021, 14, 268-276.	3.1	7
11	Comparison of family health history in surveys vs electronic health record data mapped to the observational medical outcomes partnership data model in the All of Us Research Program. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 695-703.	4.4	11
12	Planning and Conducting a Pharmacogenetics Association Study. Clinical Pharmacology and Therapeutics, 2021, 110, 688-701.	4.7	4
13	Immunopharmacogenomics: Mechanisms of HLAâ€Associated Drug Reactions. Clinical Pharmacology and Therapeutics, 2021, 110, 607-615.	4.7	29
14	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. Clinical Pharmacology and Therapeutics, 2021, 110, 559-562.	4.7	6
15	Racial, ethnic, and gender differences in obesity and body fat distribution: An All of Us Research Program demonstration project. PLoS ONE, 2021, 16, e0255583.	2.5	16
16	Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial. Clinical and Translational Science, 2021, 14, 2532-2543.	3.1	9
17	Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans. Frontiers in Pharmacology, 2021, 12, 749786.	3.5	10
18	Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches. Frontiers in Pharmacology, 2021, 12, 812830.	3.5	1

#	Article	IF	Citations
19	Geographic Variation in Obesity at the State Level in the All of Us Research Program. Preventing Chronic Disease, 2021, 18, E104.	3.4	6
20	Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1407-1415.	5.6	18
21	Approach to High Volume Enrollment in Clinical Research: Experiences from an All of Us Research Program Site. Clinical and Translational Science, 2020, 13, 685-692.	3.1	7
22	Genome-Wide Association Study Identifies Variation in ABO As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia. Blood, 2020, 136, 38-39.	1.4	1
23	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annual Review of Pharmacology and Toxicology, 2019, 59, 463-486.	9.4	42
24	Evolution of Next Generation Therapeutics: Past, Present, and Future of Precision Medicines. Clinical and Translational Science, 2019, 12, 560-563.	3.1	1
25	Unveiling the Genetic Architecture of Human Disease for Precision Medicine. Clinical and Translational Science, 2019, 12, 3-5.	3.1	3
26	PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 288-302.	1.0	10
27	From Big Data to Precision Medicine. Frontiers in Medicine, 2019, 6, 34.	2.6	273
28	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
29	Psychological and Genetic Predictors of Pain Tolerance. Clinical and Translational Science, 2019, 12, 189-195.	3.1	15
30	Genome-Wide Association Study in African Americans with Acute Respiratory Distress Syndrome Identifies the Selectin P Ligand Gene as a Risk Factor. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1421-1432.	5.6	50
31	Pharmacogenomics of Drug Allergy. , 2018, , 39-51.		0
32	Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure. Expert Review of Precision Medicine and Drug Development, 2018, 3, 319-329.	0.7	3
33	Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?. Pharmacogenomics, 2018, 19, 1413-1422.	1.3	8
34	A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers. Nature Communications, 2018, 9, 3522.	12.8	13
35	Single nucleotide polymorphisms in the MYLKP1 pseudogene are associated with increased colon cancer risk in African Americans. PLoS ONE, 2018, 13, e0200916.	2.5	10
36	Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Science Translational Medicine, 2017, 9, .	12.4	105

#	Article	IF	Citations
37	Influence of Human Leukocyte Antigen (<scp>HLA</scp>) Alleles and Killer Cell Immunoglobulinâ€Like Receptors (<scp>KIR</scp>) Types on Heparinâ€Induced Thrombocytopenia (<scp>HIT</scp>). Pharmacotherapy, 2017, 37, 1164-1171.	2.6	14
38	Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy, 2017, 37, 1150-1163.	2.6	77
39	Comparison of HLA allelic imputation programs. PLoS ONE, 2017, 12, e0172444.	2.5	58
40	Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenetics and Genomics, 2017, 27, 247-254.	1.5	54
41	Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. Blood, 2016, 128, 3043-3051.	1.4	35
42	Identifying genetically driven clinical phenotypes using linear mixed models. Nature Communications, 2016, 7, 11433.	12.8	12
43	A Study of Immunogenetic Associations with Peanut Allergy Utilizing a Novel DNA Repository. Journal of Allergy and Clinical Immunology, 2016, 137, AB25.	2.9	0
44	A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. Pharmacogenomics Journal, 2016, 16, 231-237.	2.0	47
45	Clinical and Genetic Factors Associated With Cutaneous Squamous Cell Carcinoma in Kidney and Heart Transplant Recipients. Transplantation Direct, 2015, 1, 1-7.	1.6	26
46	A genome-wide association study of heparin-induced thrombocyto - penia using an electronic medical record. Thrombosis and Haemostasis, 2015, 113, 772-781.	3.4	49
47	Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 125-135.	6.6	17
48	<scp>PROX1</scp> Gene Variant is Associated with Fasting Glucose Change After Antihypertensive Treatment. Pharmacotherapy, 2014, 34, 123-130.	2.6	9
49	Biobanks and Electronic Medical Records: Enabling Cost-Effective Research. Science Translational Medicine, 2014, 6, 234cm3.	12.4	118
50	Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. Diabetes Research and Clinical Practice, 2014, 104, 363-369.	2.8	3
51	Innovation in Clinical Pharmacy Practice and Opportunities for Academicâ€“Practice Partnership. Pharmacotherapy, 2014, 34, e45-54.	2.6	24
52	Exome Sequencing Implicates an Increased Burden of Rare Potassium Channel Variants in the Risk of Drug-Induced Long QT Interval Syndrome. Journal of the American College of Cardiology, 2014, 63, 1430-1437.	2.8	70
53	Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. Journal of Translational Medicine, 2013, 11, 12.	4.4	4
54	Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenetics and Genomics, 2013, 23, 697-705.	1.5	12

#	Article	IF	Citations
55	Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics Journal, 2013, 13, 430-436.	2.0	18
56	Mechanistic Phenotypes: An Aggregative Phenotyping Strategy to Identify Disease Mechanisms Using GWAS Data. PLoS ONE, 2013, 8, e81503.	2.5	15
57	Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Review of Cardiovascular Therapy, 2009, 7, 689-702.	1.5	28
58	Factors Influencing Blood Pressure Response to Trandolapril Add-On Therapy in Patients Taking Verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). American Journal of Cardiology, 2007, 99, 1549-1554.	1.6	22
59	The essential research curriculum for doctor of pharmacy degree programs â€“ 2021. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	4